Clinical Trials Logo

Bladder Cancer clinical trials

View clinical trials related to Bladder Cancer.

Filter by:

NCT ID: NCT00808639 Active, not recruiting - Bladder Cancer Clinical Trials

Dose-Dense MVAC With Pegfilgrastim Support in Subjects With Muscle-Invasive Urothelial Carcinoma

Start date: December 2008
Phase: Phase 2
Study type: Interventional

The purpose of this research study is to test the effectiveness of neoadjuvant chemotherapy in combination with pegfilgrastim followed by radical surgery in patients with muscle-invasive urothelial carcinoma.

NCT ID: NCT00756639 Active, not recruiting - Bladder Cancer Clinical Trials

Prophylactic Cranial Irradiation (PCI) for Small Cell Carcinoma of the Urothelium

Start date: July 21, 2008
Phase: Phase 2
Study type: Interventional

The goal of this clinical research study is to learn if whole brain radiation can lower the chances of developing brain tumors in patients with small cell carcinoma of the urinary tract, including the bladder. The safety of whole brain radiation will also be studied.

NCT ID: NCT00745355 Active, not recruiting - Bladder Cancer Clinical Trials

Quality of Life in Patients With Bladder Cancer

Start date: August 2008
Phase:
Study type: Observational

The purpose of this study is to learn about the quality of life of people living with bladder cancer. We are interested in learning about how the treatments for bladder cancer affect people. We plan to use the findings from this study to help doctors provide better care and information to patients with bladder cancer.

NCT ID: NCT00633204 Active, not recruiting - Bladder Cancer Clinical Trials

Peptide Vaccine Focusing on Prevention of the Recurrence for Bladder Cancer

Start date: February 2008
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the clinical efficacy for the prevention of the recurrence for bladder cancer after TUR-Bt

NCT ID: NCT00579514 Active, not recruiting - Breast Cancer Clinical Trials

Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients

Start date: March 2000
Phase: N/A
Study type: Interventional

The basic premise of this research proposal is to determine whether there is any significant association between germline polymorphisms and cancers of colon, bladder, breast, testicular, prostate, ovaries, kidney, lung, lymphoid organs, and head and neck. This is an exploratory study designed to generate hypotheses for further research.

NCT ID: NCT00567684 Active, not recruiting - Bladder Cancer Clinical Trials

Computed Tomography Urography (CTU) vs Intravenous Urography (IVU) on Patients at Risk of Urothelial Tumors

Start date: November 15, 2007
Phase: N/A
Study type: Interventional

The goal of this clinical research study is to use computed tomography urography (CTU) scans and intravenous urography (IVU) scans to check the status of urothelial cancer, in order to try to learn the level of effectiveness of possibly using CTU by itself in future patients.

NCT ID: NCT00380029 Active, not recruiting - Bladder Cancer Clinical Trials

Erlotinib Before and After Surgery in Treating Patients With Muscle-Invasive Bladder Cancer

NRR
Start date: May 2006
Phase: Phase 2
Study type: Interventional

RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving erlotinib before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving erlotinib after surgery may kill any tumor cells that remain after surgery. PURPOSE: This phase II trial is studying how well erlotinib works when given before and after surgery in treating patients with muscle-invasive bladder cancer.

NCT ID: NCT00126958 Active, not recruiting - Bladder Cancer Clinical Trials

Cost-Effectiveness in Bladder Cancer

Start date: July 2002
Phase: Phase 4
Study type: Observational

This randomized clinical multicentre trial aims to evaluate the efficacy of microsatellite analysis on voided urine to detect tumour recurrences in the follow-up of patients with superficial urothelialcell carcinoma (UCC). Further, this study aims to identify subgroups of patients with a low risk of tumour recurrence using clinico-pathologic tumour characteristics in combination with a genetic marker (FGFR3 gene), such that the frequency of follow-up contact can be reduced. The overall objective is to reduce the frequency of cystoscopy during follow-up in patients with superficial UCC, leading to an improvement in quality of life at equal or lower costs. This study evaluates the cost-effectiveness of follow-up in bladder cancer.

NCT ID: NCT00082706 Active, not recruiting - Bladder Cancer Clinical Trials

Fluorouracil, Leucovorin, Gemcitabine, and Cisplatin in Treating Patients With Metastatic or Unresectable Adenocarcinoma of the Urothelium or Urachal Remnant

Start date: April 23, 2003
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy, such as fluorouracil, leucovorin, gemcitabine, and cisplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving fluorouracil together with leucovorin, gemcitabine, and cisplatin works in treating patients with metastatic or unresectable adenocarcinoma of the urothelium or urachal remnant (part of the bladder).

NCT ID: NCT00054626 Active, not recruiting - Bladder Cancer Clinical Trials

Cisplatin and Gemcitabine Compared With Observation in Treating Patients Who Have Undergone Surgery for Bladder Cancer

Start date: September 2001
Phase: Phase 3
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. It is not yet known if combination chemotherapy is effective in preventing relapse in patients who have undergone radical cystectomy for bladder cancer. PURPOSE: Phase III trial to compare the effectiveness of cisplatin combined with gemcitabine with that of observation in treating patients with bladder cancer who have undergone surgery to remove the bladder.